Immunodiagnostic Systems Holdings Plc. (IDH.L) announced its final results for the year ended 31 March 2013. Profit for the year attributable to owners of the parent rose to 7.80 million pounds from last year's 4.74 million pounds, with earnings per share improving to 27.2 pence from the previous year's 16.2 pence.
Annual profit before tax grew to 10.04 million pounds from 7.25 million pounds in the prior year. Adjusted profit before tax was 9.8 million pounds, compared to 12.4 million pounds last year.
Group revenue for the year declined 7.3% to 49.8 million pounds from last year's 53.7 million pounds, with strong automated revenue growth of 23.7% and other income growth of 44.9%, partly offsetting continued declines in manual revenues (25.1%).
Patrik Dahlen, CEO of IDS, said, "We will continue to execute on our strategic plan and drive change within the business in the current year and beyond."
The company said that its board has proposed a dividend for the year of 3.0 pence, compared to 2.75 pence subject to the approval of shareholders at the Annual General Meeting. The dividend will be paid on 23 August 2013 to shareholders on the register at the close of business on 26 July 2013.
The company noted that trading for the first two months of the current financial year was in line with management expectations. The Board continues to believe that revenues in the current financial year will be similar to those achieved in the year ended 31 March 2013.
The company said it remains on track in 2013/14 for further FDA clearances for 1,25 dihydroxy vitamin D, osteocalcin, renin, aldosterone, BAP and P1NP and European product launches for cortisol, Bone TRAP and MGP.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.